OTC
0.55USD
-0.02 (-3.51%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
133.1M
P/E
—
EPS
—
Beta
1.09
52W range
0.31-0.84
Day range
0.53–0.56
Open
0.56
Prev close
0.57
Volume
81.5K
Avg volume
384.7K
Dividend
12.19
IPO
1981-12-11
https://www.marketbeat.com/instant-alerts/vaxart-q2-earnings-call-highlights-2026-08-09/ · 8/9/2026+0.60
https://www.businesswire.com/news/home/20260205922159/en/Hagens-Berman-Sobol-Shapiro-LLP-and-ScottScott-Attorneys-at-Law-LLP-Announce-a-Class-Action-for-All-Vaxart-Shareholders-that-May-Include-You-Even-if-You-Participated-in-the-Previous-Partial-Settlement-with-Vaxart/ · 2/9/2026-0.60
https://seekingalpha.com/article/4843652-vaxart-inc-vxrt-q3-2025-earnings-call-transcript · 11/14/2025+0.00
https://www.prnewswire.com/news-releases/dynavax-reports-third-quarter-2025-financial-results-and-announces-new-100-million-share-repurchase-program-302606025.html · 11/5/2025+0.50
https://www.prnewswire.com/news-releases/dynavax-enters-exclusive-license-agreement-for-vaxarts-novel-oral-covid-19-vaccine-program-302606056.html · 11/5/2025+0.80
https://www.reuters.com/business/healthcare-pharmaceuticals/us-orders-vaxart-stop-covid-19-trial-amid-mrna-wind-down-2025-08-13/ · 8/13/2025-1.00
Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
